Keyphrases
Ado-trastuzumab
50%
Adverse Events
28%
Clinical Outcomes
10%
Clinical Practice
16%
Clinical Testing
10%
Clinical Trial Registry
28%
Clinical Trials
79%
Core Outcome Set
100%
Data Extraction
26%
Data Sharing
50%
Data Sharing Practices
50%
Drug Development
50%
Drug Efficacy
10%
Extracted Data
11%
FDA-approved Drugs
20%
Future Doctors
10%
Immune Thrombocytopenic Purpura
100%
Inferential Statistics
10%
Instructions to Authors
14%
Median Overall Survival
10%
Median Progression-free Survival
10%
Monotherapy
10%
Objective Response Rate
20%
Off-label Indications
10%
Ophthalmology
29%
Ophthalmology Journal
50%
Overall Survival
10%
Patient Benefit
50%
Patient Outcomes
60%
Patient Risk
50%
Primary ITP
33%
Progression-free Survival
10%
Quality of Life
10%
Randomized Controlled Trial
50%
Reporting Guidelines
50%
Risk Outcomes
50%
Risk-benefit
50%
Sectional Analysis
50%
Survival Response
10%
T-DM1
50%
Transplantation
50%
Trastuzumab Emtansine
10%
Treatment Burden
10%
Trial Characteristics
10%
Trial Outcomes
13%
Trial Participants
10%
Trial Registration
50%
Trial Reporting
16%
Trialists
50%
Web-based Survey
50%